Lisocabtagene maraleucel (Breyanzi®) is recommended by National Comprehensive Cancer Network® (NCCN®)2

NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.

NCCN, National Comprehensive Cancer Network®, (NCCN®).

Learn about Breyanzi®: the CAR T with the broadest patient eligibility for 2L LBCL patients1
Safety evaluated in a broad range of patients across Breyanzi trials

This website is best viewed
using the horizontal display on
your tablet device.

This website is best viewed
using the vertical display on
your mobile device.